文献速递泌尿生殖技术与安全CTPET

评估同期增强诊断CT对PSMA-PET/CT判读的附加价值

Evaluating the Added Value of Concurrent Contrast-enhanced Diagnostic CT for PSMA-PET/CT Interpretation.
PubMed 文献 · Acad Radiol · 2024-08-14

这项回顾性多阅片者研究分析前列腺癌患者的F-18-匹夫卢司他PSMA-PET/CT联合胸部/腹盆部诊断性CT图像,6名核医学放射阅片者随机判读有无诊断性CT的PSMA-PET/CT并报告诊断确定性。结果显示联合诊断性CT未显著提高总体诊断确定性(92%±16 vs 92%±17,p=0.43),但在初始分期时联合诊断性CT似乎略有优势(89%±16 vs 93%±17,p=0.08)。

要点

  • PSMA-PET/CT联合诊断性CT与单独PSMA-PET/CT的总体诊断确定性相似(92%±16 vs 92%±17,p=0.43)。
  • 不同解剖部位或临床参数下,加做诊断性CT均无显著优势。
  • 初始分期时联合诊断性CT似乎略有优势(89%±16 vs 93%±17,p=0.08)。

核心结论

  • 不同培训水平的阅片者之间PSMA-PET/CT可获得良好的一致性;对多数适应症而言,同期使用诊断性CT并未显著提高诊断确定性,但可能对初始分期有用。

研究设计与样本

  • 回顾性多阅片者研究,分析FDA批准该PET药物后前6个月内前列腺癌患者的F-18-匹夫卢司他PSMA-PET/CT联合胸部/腹盆部诊断性CT图像,6名核医学放射阅片者参与判读。

诊断标准与关键数值

  • FSMA-PET/CT总体扫描确定性:Finn可靠性系数0.85(p<0.01)。
  • 联合诊断性CT-PET/CT总体扫描确定性:Finn可靠性系数0.59(p<0.01)。
  • 总体扫描确定性:单独PSMA-PET/CT为92%±16,联合诊断性CT-PET/CT为92%±17(p=0.43)。
  • 初始分期时:单独PSMA-PET/CT为89%±16,联合诊断性CT-PET/CT为93%±17(p=0.08)。

临床应用与阅片要点

  • 作者认为,同期使用诊断性CT可能对前列腺癌初始分期有用,但对多数其他适应症并未显著提高诊断确定性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To determine whether concurrent contrast-enhanced diagnostic CT (DxCT) confers added diagnostic certainty compared to PSMA-PET/CT alone.

MATERIALS AND METHODS: This retrospective multi-reader study analyzed imaging comprising combined F-18-piflufolastat PSMA-PET/CT with diagnostic chest/abdominopelvic CT from prostate cancer patients within the first 6 months of FDA-approval of the PET agent. Six nuclear radiology readers were randomly presented with PSMA-PET/CT studies with or without DxCT and asked to report their diagnostic certainty for PSMA-avid lesions found on PET. Subsequently, readers re-reviewed the same study after an interlude (with the CT if not previously presented and vice-versa) to determine if DxCT altered their diagnostic assessment. Inter-rater concordance was assessed on a subset of images read by all readers. Diagnostic certainties for PSMA-PET/CT with and without DxCT were compared, and the variables for which DxCT may add value were examined.

RESULTS: Good inter-rater concordance across readers was noted for both PET/CT (Finn's coefficient of reliability for overall scan certainty: 0.85,p < 0.01) and combined DxCT-PET/CT (0.59,p < 0.01). Overall certainty and concordance between PET/CT and combined DxCT-PET/CT datasets were similar (overall scan certainty: 92% ± 16 vs. 92% ± 17,p = 0.43), with no significant advantage for adding DxCT across different anatomic locations or clinical parameters. A slight predilection for combined DxCT-PET/CT was noted when interpreting images acquired for the initial staging of prostate cancer (89% ± 16 vs. 93% ± 17,p = 0.08).

CONCLUSION: Good inter-reader concordance can be achieved across different training levels with PSMA-PET/CT. Furthermore, using DxCT concurrent with PSMA-PET/CT does not significantly improve diagnostic certainty for most indications but may be useful for initial staging.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Trinh K, Chow DZ, Park H, et al. Evaluating the Added Value of Concurrent Contrast-enhanced Diagnostic CT for PSMA-PET/CT Interpretation. Acad Radiol. 2024. PMID: 39147641. doi:10.1016/j.acra.2024.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。